Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States (updated 2/22/22.)

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States - recent changes (last updated February 22, 2022):
Added considerations for an 8-week interval between the first and second doses of a primary mRNA vaccine schedule. Update posting 2-22-22.